PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers


You May Also Like

AIT Therapeutics Reports Year End 2017 Financial Results

Expects first regulatory filing for the NO Generator and Delivery System in persistent pulmonary ...

Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET

CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical ...